Market Overview

Analysts Love CVS Health Shares Following Aetna Deal

Share:
Analysts Love CVS Health Shares Following Aetna Deal
Related CVS
Molina Wins New Bulls On Cost Saving, Margin Opportunities
Barron's Picks And Pans: Apple, Exxon, Morgan Stanley And More
M&A Updates: CVC Capital Is Interested In French Insurer April SA (Seeking Alpha)
Related AET
9 Policy Catalysts For Health Care Investors To Watch Before Year's End
The Health Care Stocks With A Lot Riding On The Midterm Elections
M&A Updates: CVC Capital Is Interested In French Insurer April SA (Seeking Alpha)

CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET) on Monday received the final state approval for their $69 billion merger, and CVS said it expects to the deal to close this week. CVS stock has dramatically lagged the S&P 500 in the past three years, but analysts love the company’s post-merger opportunities.

Cantor Fitzgerald Initiates

Cantor Fitzgerald analyst Steven Halper initiated coverage of CVS stock with an Overweight rating and $96 price target. According to Halper, CVS and Aetna will soon create a brand new healthcare model in the U.S.

“We expect CVS to integrate AET clinical capabilities to enable a strong patient experience at its widely recognizable MinuteClinic locations,” Halper wrote in the note.

He said CVS will likely transition Aetna member patients to lower-cost care options, such as MinuteClinics and CVS specialty infusion service Coram.

CVS plans to begin rolling out its Aetna concept clinics in early 2019, so investors should soon get a glimpse of what to expect in the future.

Considering the growth potential of the new business model, the value of CVS’s digital assets and the fact that CVS shares currently trade at just 9.9 times Cantor’s 2019 EPS projections, Halper says there are a lot of things for investors to like about the stock.

Tigress Take

Tigress Financial analyst Ivan Feinseth said the end result of the merger will be CVS gaining both market share and mindshare in an increasingly dynamic health care industry.

“The combined company will be better positioned to capitalize on the healthcare industry’s changing dynamics including new reimbursement models and the shift to value-based healthcare services,” Feinseth said.

He also sees upside for CVS stock and recommends investors buy shares at current levels.

CVS traded around $78.10 Tuesday morning following the bullish commentary. Investors will be watching closely the rest of the week for an official announcement that the merger has been finalized.

Related Links:

9 Policy Catalysts For Health Care Investors To Watch Before Year's End

Goldman Sachs Bearish On Standalone Rite Aid

Photo credit: Ildar Sagdejev (Specious) - Own work, GFDL, via Wikimedia Commons

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2018BarclaysInitiates Coverage OnOverweight
Nov 2018Goldman SachsReinstatesNeutral
Nov 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Initiation M&A Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (AET + CVS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AITKeyBancUpgrades0.0
MDCitigroupUpgrades0.0
PUMPBarclaysUpgrades20.0
ECPGOppenheimerUpgrades37.0
RACEBernsteinUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Raymond James Sees $1B Potential In Loxo Oncology's Vitrakvi, LOXO-95

Insider Response To Tech's Volatile Autumn